BMS 986187 is a selective positive allosteric modulator of the delta opioid receptor (DOP). Its primary application lies in research settings, particularly in neuroscience and pharmacology, where it is used to study the function and signaling of delta opioid receptors. Unlike traditional opioid agonists, BMS 986187 enhances receptor activity only in the presence of endogenous opioids, which may reduce the risk of side effects such as respiratory depression or addiction. This makes it a valuable tool for investigating pain modulation pathways without directly activating the receptor.

It has shown potential in preclinical studies for managing chronic pain and mood disorders, including anxiety and depression, due to the delta receptor's role in emotional regulation. Additionally, because of its allosteric mechanism, BMS 986187 helps researchers explore biased signaling and receptor subtype selectivity, contributing to the development of safer, more effective analgesics. It is not used clinically and remains strictly for experimental research.